Will the FDA grant Fast Track designation to RLY-2608 by March 31, 2025? | Binary | | | 4 months ago | |
Will Lirafugratinib generate at least $100 million in sales by end of 2026? | Binary | | | 20 days ago | |
Will Relay Therapeutics receive the first commercial milestone payment from Elevar by end of 2025? | Binary | | | 20 days ago | |
Will Relay Therapeutics announce further positive data from the RLY-2608 study by December 31, 2024? | Binary | | | 4 months ago | |
What will be the percentage increase in Relay Therapeutics' stock (RLAY) by December 31, 2024? | Categorical | | | 4 months ago | |
Will Relay Therapeutics' stock (RLAY) increase by 10% or more by October 31, 2024? | Binary | | | 4 months ago | |
What will be the market cap rank of Relay Therapeutics among biotech companies by December 31, 2024? | Categorical | | | 4 months ago | |
How many additional indications will Lirafugratinib be approved for by end of 2026? | Categorical | | | 20 days ago | |
Will Lirafugratinib receive FDA approval for FGFR2-driven cholangiocarcinoma by end of 2025? | Binary | | | 20 days ago | |
Which country will first approve Lirafugratinib for FGFR2-driven cholangiocarcinoma by end of 2025? | Categorical | | | 20 days ago | |
Will Lirafugratinib be approved by FDA, EMA, or both by end of 2026? | Categorical | | | 20 days ago | |
What will be the outcome of the next major clinical trial phase for RLY-2608 by December 31, 2025? | Categorical | | | 4 months ago | |